This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cubist Pharmaceuticals Appoints Jane Henney To Board Of Directors

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the appointment of Jane E. Henney, M.D. to its Board of Directors. Dr. Henney currently is a Professor of Medicine at the University of Cincinnati College of Medicine. With the addition of Dr. Henney, the Cubist Board of Directors consists of 11 members, 10 of whom are independent.

“Jane brings a tremendous breadth of experience from her career, and we are delighted to welcome her to our Board,” said Kenneth Bate, non-executive Chairman of the Board of Directors of Cubist. “The medical and health policy insights Jane has gained over her years as FDA Commissioner and as a leader of large and successful medical organizations will prove invaluable to Cubist as we continue to grow and expand our acute care business.”

In addition to serving as a Professor of Medicine from 2003-2008, Dr. Henney also served as the Senior Vice President and Provost of University of Cincinnati’s Academic Health Center. In 2008 Dr. Henney was appointed to her current position as a Professor of Medicine at the University of Cincinnati College of Medicine. Dr. Henney served as the Senior Scholar at the Association of Academic Health Centers (AAHC) from 2001-2003. Before joining the AAHC, Dr. Henney served as the Commissioner of the U.S. Food and Drug Administration (FDA) from 1998-2001. From 1994-1998 she was Vice President for Health Sciences at the University of New Mexico. Dr. Henney worked at the FDA as Deputy Commissioner of Operations from 1992-1994. Before her time at the FDA, Dr. Henney served in a variety of senior leadership positions, including interim Dean of the College of Medicine at the University of Kansas School of Medicine. Prior to this position, Dr. Henney held a variety of positions at the National Cancer Institute including Deputy Director from 1980-1985. From 1976-1985, Dr. Henney served in a variety of roles at the National Institutes of Health (NIH), eventually becoming its Deputy Director in 1982. Dr. Henney received her undergraduate degree from Manchester College, her medical degree from Indiana University and her training in Oncology from M.D. Anderson Hospital and Tumor Institute. She currently sits on the board of directors for both AmerisourceBergen Corporation and CIGNA Corporation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs